WA
BMRN icon

Whipplewood Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Whipplewood Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$226 – 690
2026
Q1 		$226 Buy
+4
New +$233 ﹤0.01% 1028
2025
Q3 		– Sell
-16
Closed -$880 – 404
2025
Q2 		$880 Sell
16
-4
-20% -$236 ﹤0.01% 1036
2025
Q1 		$636 Buy
20
+11
+122% +$740 ﹤0.01% 1095
2024
Q4 		$592 Buy
+9
New +$603 ﹤0.01% 1096

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Whipplewood Advisors's BMRN Position: Q2 2026 in Review

Whipplewood Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4 shares — an estimated $226 sold.

Whipplewood Advisors first reported a position in BMRN in Q4 2024 and held it in 4 quarters. The position peaked at $880 in Q2 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Whipplewood Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Whipplewood Advisors sold 4 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $226.
  • Whipplewood Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Whipplewood Advisors's BioMarin Pharmaceuticals position peaked at $880 in Q2 2025.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.